Priorix (MMR vaccine) / GSK - LARVOL DELTA

Anaphylaxis to MMR vaccine gelatin : practical recommendations (PubMed, Rev Med Liege) - "This article reports two pediatric cases of anaphylaxis to the M-M-RVaxPro® vaccine, attributable to porcine gelatin used as a stabilizer (14.5 mg/dose)...Key recommendations include avoidance of gelatin-containing vaccines and medications, substitution with gelatin-free alternatives (Priorix®), evaluation of food tolerance through an oral challenge test, and provision of an emergency kit with epinephrine. Hospital monitoring is recommended for future vaccinations in patients with mast cell disorders. The study highlights gelatin as the primary culprit in vaccine anaphylaxis, emphasizing the importance of systematic testing for vaccine components and proper management of sensitized patients."

Journal • Pediatrics

Adult immunization. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus • Varicella Zoster

Comparison chart: Some vaccines for adults. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus

MMR Vaccination and Hen's Egg Allergy: Bridging the Gap Between Evidence and Clinical Practice. (PubMed, Vaccines (Basel)) - " In this study, we retrospectively assessed the safety of MMR vaccination (Priorix®, GlaxoSmithKline, Belgium) in patients with HEA hospitalised at our clinic... Severe adverse reactions following MMR vaccination in patients with HEA are generally rare and are outweighed by the risks associated with natural infection and its complications. Effective communication of vaccine safety data and strengthening public trust in healthcare professionals are crucial."

Journal • Allergy • Food Hypersensitivity • Immunology • Infectious Disease • Measles • Mumps • Pediatrics • Rubella

Measles serostatus among health care workers in a university clinic in Hungary in 2024. (PubMed, Prev Med Rep) - "Newer combinations, such as MMR-II/Priorix, elicited higher antibody levels compared to old combinations...A substantial proportion of HCWs have low level of measles antibodies, especially in specific age cohorts. Targeted screening and revaccination are recommended to close immunity gaps and prevent nosocomial transmission."

Journal • Infectious Disease • Measles

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=900 | Recruiting | Sponsor: GlaxoSmithKline | N=354 ➔ 900

Enrollment change • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2360 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting | Trial completion date: May 2027 ➔ Oct 2027 | Trial primary completion date: May 2027 ➔ Oct 2027

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Real-World Evaluation of Allergic Reactions to Two MMR Vaccine Formulations in Children with Egg and/or Cow's Milk Allergy. (PubMed, Int Arch Allergy Immunol) - "MMR vaccination was generally well tolerated in children with egg and/or cow's milk allergy. While rare immediate reactions may occur with vaccines containing milk-derived proteins, these findings support continued adherence to current vaccination recommendations, with awareness of vaccine composition and appropriate vaccination settings rather than vaccine avoidance."

HEOR • Journal • Real-world evidence • Allergy • Atopic Dermatitis • Dermatitis • Dermatology • Food Hypersensitivity • Immunology • Pediatrics • Urticaria

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (clinicaltrials.gov) - P3 | N=896 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (clinicaltrials.gov) - P3 | N=896 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months (clinicaltrials.gov) - P3 | N=1200 | Completed | Sponsor: Shanghai Institute Of Biological Products | Recruiting ➔ Completed | Trial completion date: Jun 2025 ➔ Mar 2025

Head-to-Head • Trial completion • Trial completion date • Infectious Disease • Measles • Mumps • Rubella

IL-ImmuneRTC: A Pilot Study to Evaluate the Therapeutic Efficacy of Intra-Lesional Immunotherapy in Patients Aged 10-60 Years With Recalcitrant Tinea Cruris and Corporis (clinicaltrials.gov) - P=N/A | N=50 | Recruiting | Sponsor: Abeer Mohamed Abdelaziz Elkholy

New trial • Dermatology

Allergic Adverse Reactions Following Measles-Mumps-Rubella Vaccination in Children with Food Allergy: A Prospective Multicenter Study. (PubMed, Pediatr Allergy Immunol Pulmonol) - "Of the patients, 126 (62.4%) received Tresivac®, while 76 (37.6%) received Priorix®. It was determined that the cut-off values for cow's milk and egg white spIgE were found to be significant in identifying children at risk for allergic reactions following MMR vaccination. Children with food allergies who had a family history of atopy were found to have a higher risk of allergic reactions."

Clinical • Journal • Allergy • Cardiovascular • Dermatology • Food Hypersensitivity • Immunology • Infectious Disease • Measles • Mumps • Rubella • Urticaria

Implementing an MMR vaccination programme for adults living with HIV in response to a measles outbreak in London, UK (IAS-HIV 2025) - "We offered both the MMRVAXPRO and PRIORIX vaccines to provide an alternative for clients who declined porcine gelatine. Integrating measles immunity testing and MMR vaccination into routine HIV care is feasible. It ensures ease of access to vaccination and promotes vaccine uptake, improving health outcomes for people living with HIV."

Clinical • Human Immunodeficiency Virus • Infectious Disease • Measles • CD4

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=900 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Recruiting | Sponsor: Sanofi | Trial completion date: May 2027 ➔ Aug 2027 | Trial primary completion date: May 2027 ➔ Aug 2027

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

In brief: Prevention of measles. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Infectious Disease • Measles

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=900 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P3 trial • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2320 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2320 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months (clinicaltrials.gov) - P3 | N=1200 | Recruiting | Sponsor: Shanghai Institute Of Biological Products | Not yet recruiting ➔ Recruiting

Enrollment open • Head-to-Head • Infectious Disease • Measles • Mumps • Rubella

Persistence of Antibodies against Measles, Mumps, and Rubella after the Two-Dose MMR Vaccination: A 7-Year Follow-Up Study. (PubMed, Vaccines (Basel)) - P4 | "We followed a cohort of healthy children from a clinical trial (ClinicalTrials.gov NCT02408926) where they were administered either the Priorix vaccine (GlaxoSmithKline Biologicals, Rixensart, Belgium) or M-M-RII (Merck & Co., Kenilworth, NJ, USA) at 9 months and 2.5 years of age...Over the 4.5 years following the two-dose MMR vaccination, we observed a decline in the seroprotection rates against measles and mumps, but not rubella. Longitudinal monitoring of antibody persistence, among other strategies, will help predict population-level immunity and inform public health interventions to address potential future outbreaks."

Journal • Infectious Disease • Measles • Mumps • Rubella